What's breaking now, across thousands of outlets.
In his Sunday column, Jim Cramer explains why Amazon is his favorite hyperscaler after second-quarter earnings season.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
AstraZeneca Plc has explored an acquisition of Bristol Myers Squibb Co., in a megadeal that would create one of the world’s largest drugmakers, according to people familiar with the matter.
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. rival Bristol Myers Squibb.
Experts give tips on how to manage inflation, which is driven mainly by higher prices of food, cars, health insurance and petrol.
AI-native businesses need real-time finance, not monthly reports. Learn how predictive FP&A, telemetry, and AI cost governance are reshaping enterprise finance.
At the stage of the new steel safeguard measure passing through joint adoption, the EU’s legislative triumvirate signaled that Ukraine would receive special consideration, while its industry faces…
